AIS
AVEO

AlphaOne Investment Services’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

AlphaOne Investment Services’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-430
Closed -$12K – 482
2017
Q4 		$12K Buy
+430
New +$13.3K ﹤0.01% 290

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

AlphaOne Investment Services's AVEO Position: Q1 2018 in Review

AlphaOne Investment Services sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2018, closing a stake of 430 shares — an estimated $12K sold.

AlphaOne Investment Services first reported a position in AVEO in Q4 2017 and held it in 1 quarter. The position peaked at $12K in Q4 2017. 90 funds tracked by Wall St. Rank hold AVEO as of Q1 2018.

  • AlphaOne Investment Services reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • AlphaOne Investment Services sold 430 AVEO Pharmaceuticals, Inc. shares in Q1 2018, an estimated $12K.
  • AlphaOne Investment Services first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • AlphaOne Investment Services's AVEO Pharmaceuticals, Inc. position peaked at $12K in Q4 2017.
  • 90 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2018.

Based on AlphaOne Investment Services's 13F filing for Q1 2018, filed 14 May 2018.